-20℃ 3 years powder
-80℃ 2 years in solvent
CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3, CCT241736, an advanced analog of CCT137690, is a preclinical development candidate for the treatment of human malignancies, and in particular AML in adults and children.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | 68.00 | |
10 mg | In stock | 110.00 | |
25 mg | In stock | 218.00 | |
50 mg | In stock | 430.00 | |
100 mg | In stock | 671.00 |
Description | CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3, CCT241736, an advanced analog of CCT137690, is a preclinical development candidate for the treatment of human malignancies, and in particular AML in adults and children. |
Targets&IC50 | FLT3, Aurora Kinase, |
In vivo | UNC2025 was capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow. |
Molecular Weight | 456.37 |
Formula | C22H23Cl2N7 |
CAS No. | 1402709-93-6 |
-20℃ 3 years powder
-80℃ 2 years in solvent
H2O: < 0.1 mg/mL (insoluble)
DMSO: 75 mg/mL (164.34 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.